Clinical trial NCT02632253: Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease
Official title: Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease (GUCH)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Congenital Heart Defects
Keywords: exercise therapy
GUCH
ventricular ejection fraction
HIIT
MICE
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
Collaborators: name: Schweizerische Herzstiftung
First posted: 2015-12-16
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with congenital heart disease have long been discouraged from participating in physical exercise which has led to impaired exercise capacity in this population. Since low physical and cardiorespiratory fitness has been shown to be a predictor for hospitalization and mortality in grown-up patients with congenital heart disease (GUCH), aerobic endurance training has been recommended recently to improve exercise capacity. The aim of this study is to compare two types of training, namely high-intensity interval training (HIIT) and moderate-intensity continuous exercise (MICE), with regard to improving exercise capacity without adverse effects on heart structure, function and rhythm in the setting of a 12-week outpatient cardiac rehabilitation (CR) program in GUCH with a remaining pathology involving the right and/or left ventricles. Primary endpoint will be change in exercise capacity (maximal oxygen consumption) over the 12-week CR. Secondary endpoints will be changes of the right or left ventricles as well as vascular function.

Patients with GUCH and reduced function of the right ventricle will be recruited and informed about the study within the first two weeks of CR. At the end of week 3 of the CR with supervised MICE, randomization to 9 weeks of twice weekly either HIIT or MICE takes place.

MICE training is performed at an intensity of 70-85% of maximum heart rate (HRmax) for 38 min. HIIT consists of four 4 min bouts of high-intensity exercise (90-95% of HRmax), interspersed by 3 min low-intensity intervals (50-60% of HRmax). All patients complete one additional endurance activity per week in their own time with a duration of 30-60 min at moderate intensity monitored by their smart phone.

Change in peak oxygen uptake as well as maximal exercise capacity at the end of an incremental cardiopulmonary exercise test will be assessed between week 3 and 12. Vascular function will be assessed at the same time. Volumes and function of the right and left ventricles will be measured by cardiac magnetic resonance imaging (CMR) upon inclusion into the study and at completion of the intervention. Furthermore, laboratory markers for heart failure as well as occurrence of irregular fast heart beats will be assessed.

Detailed description: Background

Adults with congenital heart disease have long been recommended to refrain from physical exercise. Therefore, they often have significant reduction in exercise capacity. Only recently, regular exercise has been shown to be safe and is nowadays recommended for patients with congenital heart disease. As a result, exercise based rehabilitation programs have been implemented in order to improve exercise capacity and avoid adverse effects associated with inactive lifestyle.

Several studies have shown that high-intensity interval training (HIIT) is more effective than moderate-intensity continuous exercise training (MICE) at improving functional capacity and quality of life in stable cardiac patients and can be performed safely. It has therefore emerged as a new and important exercise modality in cardiac rehabilitation centers all over Europe for stable cardiac patients with left ventricular (LV) dysfunction. However, its safety and efficacy has not yet been tested in adults with congenital heart disease and to date there are no studies who have evaluated whether short term peaks of pulmonary artery or systemic pressure during bouts of 4 min of high-intensity exercise negatively affects the subpulmonary or systemic ventricle in GUCH patients. The investigators hypothesized that the positive effects of HIIT on exercise capacity and vascular function found in patients with ischemic cardiomyopathy can be transferred to the population of GUCH patients, and that short-term bouts of high-intensity exercise will not negatively affect cardiac morphology and function.

Objective

To test the superiority of a 9-week high-intensity interval training (HIIT) over a standard rehabilitation training based on moderate-intensity continuous exercise (MICE) on exercise capacity in patients with grown-up congenital heart disease (GUCH) with a residual pathology involving the right and/or left ventricle (RV/LV).

Methods

Measurements will be performed before and after a 12 week intervention with either HIIT or MICE training. Patients will undergo cardiopulmonary exercise testing on a cycle ergometer to determine exercise capacity and VO2 peak. Cardiac magnetic resonance imaging will be performed for ventricular volumes, mass and function. Vascular function will be assessed by arterial stiffness measurement. Physical exercise, quality of life will be evaluated by questionnaires.

During the 4th and the 12th week of the rehabilitation training, heart rate variability will be measured in the morning following a training, and blood samples will be taken after a training session to analyse markers of myocardial stress (hs Troponin and N-terminal of the prohormone brain natriuretic peptide, NT pro-BNP). Compliance and acceptance of training will be assessed by questionnaires.

Eligibility criteria: Inclusion Criteria:

* Tetralogy of Fallot
* Double outlet right ventricle
* Transposition of the great arteries with atrial or arterial switch
* Treated or untreated pulmonary valvular or pulmonary artery stenosis
* Reduced right ventricular function after correction of atrial septal defect (ASD), atrio-ventricular septal defect (AVSD) or ventricular septal defect (VSD) (≤40%)
* Ebstein anomaly
* Patients with a systemic right ventricle like d-transposition of the great arteries (d-TGA) with previous atrial switch operation or cc-TGA

Exclusion Criteria

* Inability to participate in a 3-month training program in Bern
* New York Heart Association class ≥ III
* Ventricular function ≤30% of either the systemic or the sub-pulmonary ventricle
* Moderate to severe LV outflow tract obstruction (valvular, subvalvular, due to asymmetric septum hypertrophy, or aortic coarctation) with mean gradient \>30 mmHg by echo
* Severe RV outflow tract obstruction with peak gradient ≥60 mmHg by echo
* Moderate to severe pulmonary hypertension with mean pulmonary artery pressure≥40 mmHg
* Resting saturation at ambient air of \<90%
* Pacemaker or Implantable Cardioverter Defibrillator
* Contraindication to perform a CMR (cerebral clips, iron-containing body implants, medical pumps)
* Recent episode of ventricular tachycardia
* Permanent atrial fibrillation
* Unstable angina or recent myocardial infarction (\<12 months)
* Recent cardiac operation \<6 months
* Ascending aortic dilatation \>45 mm in patients with bicuspid aortic valve or \>50 mm in patients without bicuspid aortic valve
* Repaired coarctation with pseudoaneurysm in MR angiography
* No consent
* Any medical condition which would prevent a patient from performing high intensity training (e.g. cardiac thrombus formation, recent valve surgery (\< 1 year), in general orthopedic, peripheral vascular, neurologic or other limitations)
* Inability to perform cardiopulmonary exercise testing
* Pregnancy

Primary outcomes:
measure: Peak oxygen uptake (VO2 peak) during maximal cardiopulmonary exercise test
timeFrame: week 1 to 12
Secondary outcomes:
measure: VO2 peak during maximal cardiopulmonary exercise test
timeFrame: week 1 to 65
measure: Ventricular Volumes by cardiac magnetic resonance imaging
timeFrame: week 1 and 12
measure: Ventricular function by cardiac magnetic resonance imaging (MR)
timeFrame: week 1 and 12
measure: Vascular function by arterial stiffness measurement
timeFrame: week 3, 12, and 65
measure: Arrhythmias quantified and characterised by ECG
timeFrame: week 3, 12, and 65
measure: N terminal pro b-type natriuretic peptide (NT- proBNP)
timeFrame: week 0, 3, 12, and 65
measure: hs Troponin
timeFrame: week 3 and 12
measure: Adherence to training
timeFrame: week 1-12
measure: Quality of life
timeFrame: week 1, 12, and 65
measure: Quality of life for heart failure
timeFrame: week 1, 12, and 65
measure: Daily physical activity
timeFrame: week 1, 12, and 65
measure: Heart rate variability
timeFrame: week 3, 12, and 65
Other outcomes:
measure: Heart rate variability
timeFrame: week 3 and 12
Locations:
city: Bern
country: Switzerland
facility: Department of Preventive Cardiology, Bern University Hospital
Study officials:
affiliation: Preventive Cardiology & Sports Medicine, University Clinic for Cardiology, University Hospital Berne, Inselspital, Bern, Switzerland
name: Christina Deluigi, MD
role: PRINCIPAL_INVESTIGATOR
References: